AbCellera Biologics (ABCL) Gains from Investment Securities (2020 - 2026)

AbCellera Biologics has reported Gains from Investment Securities for 7 years, with the latest figure at -$2.4 million in Q1 2026.

• For the quarter ending Q1 2026, Gains from Investment Securities fell 7.41% year-over-year to -$2.4 million; the trailing twelve-month figure through Mar 2026 stood at $3.2 million (up 139.0% YoY), and the FY2025 full-year result was $3.3 million, changed N/A from the prior year.
• Gains from Investment Securities for Q1 2026 stood at -$2.4 million, up from -$3.6 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $27.7 million in Q3 2024, with the low at -$35.9 million in Q4 2024.
• Historically, Gains from Investment Securities has averaged $274805.4 across 5 years, with a median of $2.5 million in 2022.
• Annual changes were most pronounced in 2022 — Gains from Investment Securities soared 1093.7% — and 2024, when it plunged 1132.42%.
• AbCellera Biologics' Gains from Investment Securities stood at -$23.1 million in 2022, then jumped by 115.04% to $3.5 million in 2023, then sank by 1132.42% to -$35.9 million in 2024, then jumped by 90.09% to -$3.6 million in 2025, then jumped by 33.14% to -$2.4 million in 2026.
• The last three Gains from Investment Securities figures came in at -$2.4 million (Q1 2026), -$3.6 million (Q4 2025), and $6.2 million (Q3 2025), per Business Quant data.